» Articles » PMID: 37173733

Neuropathology of Incidental Lewy Body & Prodromal Parkinson's Disease

Overview
Publisher Biomed Central
Date 2023 May 12
PMID 37173733
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with a loss of dopaminergic (DA) neurons. Despite symptomatic therapies, there is currently no disease-modifying treatment to halt neuronal loss in PD. A major hurdle for developing and testing such curative therapies results from the fact that most DA neurons are already lost at the time of the clinical diagnosis, rendering them inaccessible to therapy. Understanding the early pathological changes that precede Lewy body pathology (LBP) and cell loss in PD will likely support the identification of novel diagnostic and therapeutic strategies and help to differentiate LBP-dependent and -independent alterations. Several previous studies identified such specific molecular and cellular changes that occur prior to the appearance of Lewy bodies (LBs) in DA neurons, but a concise map of such early disease events is currently missing.

Methods: Here, we conducted a literature review to identify and discuss the results of previous studies that investigated cases with incidental Lewy body disease (iLBD), a presumed pathological precursor of PD.

Results: Collectively, our review demonstrates numerous cellular and molecular neuropathological changes occurring prior to the appearance of LBs in DA neurons.

Conclusions: Our review provides the reader with a summary of early pathological events in PD that may support the identification of novel therapeutic and diagnostic targets and aid to the development of disease-modifying strategies in PD.

Citing Articles

Comparing In vitro Protein Aggregation Modelling Using Strategies Relevant to Neuropathologies.

Nadais A, Martins I, Henriques A, Trigo D, da Cruz E Silva O Cell Mol Neurobiol. 2025; 45(1):24.

PMID: 40080205 PMC: 11906958. DOI: 10.1007/s10571-025-01539-z.


Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.

Wang Y, Li N, Guan W, Wang D FASEB J. 2025; 39(6):e70468.

PMID: 40079203 PMC: 11904867. DOI: 10.1096/fj.202402775RR.


Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges.

Almasi F, Abbasloo F, Soltani N, Dehbozorgi M, Moghadam Fard A, Kiani A Mol Neurobiol. 2025; .

PMID: 39998798 DOI: 10.1007/s12035-025-04788-7.


Neutrophil-to-Lymphocyte Ratio as a Biomarker for Motor Subtypes in Idiopathic Parkinson's Disease.

Awan R, Tahir O, Noor Ul Hadi S, Rehman W, Asim F Cureus. 2025; 17(1):e77440.

PMID: 39949444 PMC: 11824908. DOI: 10.7759/cureus.77440.


The centenarian blueprint: lessons in defying Parkinson's disease.

Bhidayasiri R, Aiba I, Nomoto M J Neural Transm (Vienna). 2024; 132(3):331-339.

PMID: 39729254 DOI: 10.1007/s00702-024-02875-y.


References
1.
Jellinger K . Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna). 2019; 126(8):933-995. DOI: 10.1007/s00702-019-02028-6. View

2.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

3.
Hurley M, Durrenberger P, Gentleman S, Walls A, Dexter D . Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease. J Mol Neurosci. 2015; 57(1):48-62. DOI: 10.1007/s12031-015-0576-8. View

4.
Postuma R, Lang A, Gagnon J, Pelletier A, Montplaisir J . How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012; 135(Pt 6):1860-70. DOI: 10.1093/brain/aws093. View

5.
Stefani A, Iranzo A, Holzknecht E, Perra D, Bongianni M, Gaig C . Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. 2021; 144(4):1118-1126. DOI: 10.1093/brain/awab005. View